Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins Sells 211,160 Shares

Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins sold 211,160 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares in the company, valued at $21,901,958.50. The trade was a 7.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT opened at $8.30 on Wednesday. Adaptive Biotechnologies Co. has a 1 year low of $2.28 and a 1 year high of $8.95. The stock’s 50-day simple moving average is $7.05 and its 200-day simple moving average is $5.68. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -6.19 and a beta of 1.50.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 62.06% and a negative net margin of 110.13%. During the same quarter in the prior year, the firm posted ($0.30) EPS. As a group, research analysts predict that Adaptive Biotechnologies Co. will post -1.08 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ADPT. Impact Partnership Wealth LLC increased its position in shares of Adaptive Biotechnologies by 8.8% in the 4th quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,539 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Adaptive Biotechnologies by 2.7% during the fourth quarter. Russell Investments Group Ltd. now owns 80,994 shares of the company’s stock valued at $486,000 after buying an additional 2,163 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Adaptive Biotechnologies by 4.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,916 shares of the company’s stock valued at $395,000 after buying an additional 2,625 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Adaptive Biotechnologies by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,292 shares of the company’s stock worth $188,000 after buying an additional 2,928 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Adaptive Biotechnologies by 5.6% in the 4th quarter. MetLife Investment Management LLC now owns 68,976 shares of the company’s stock worth $414,000 after acquiring an additional 3,650 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ADPT has been the topic of a number of research reports. BTIG Research raised their target price on shares of Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler raised their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. The Goldman Sachs Group upped their target price on Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Scotiabank raised their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a “sector outperform” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $8.30.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.